ADCY10 and cancer: Targeting APC activity has shown promise in an anti-tumor capacity, as the SAC inhibitors M2I-1 and TTKi, which both disrupt CDC20-SAC interactions, increase APCCDC20 activity and provide increased killing of cancer cells [31, 58–62].